|
|
Article: OXIS Out-licensed Drug BXT 51072 to Be Developed by Synvista for the Treatment of Psoriasis.
- Article from:
- Business Wire
- Article date:
- January 18, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FOSTER CITY, Calif. -- Oxis International Inc. (OTCBB:OXIS) announced today that Synvista Therapeutics Inc intends to develop ALT-2074 for the treatment of psoriasis. ALT-2074 is one of Synvista's lead compounds under development for use in cardiovascular disease. On April 9, 2007 OXIS entered into a worldwide license under which OXIS granted exclusive rights to its organoselenium portfolio of products, including BXT 51072, to Synvista Therapeutics, formerly Alteon, Inc. The license agreement expands the scope of a previous license to Alteon (formerly HaptoGuard) to include non-cardiovascular indications.
ALT-2074 (formerly BXT-51072), Synvista's lead compound ...